2010 Clinical Trials Conditions Therapy 
Project CBD
FEBRUARY 27, 2023
Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. They report that oral feeding of a single dose of cannabis oil was enough to mitigate some hallmarks of the condition in mice. It’s not a new idea.
Cannabis Law Report
OCTOBER 9, 2021
A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder (PTSD)—the latest example of how the psychedelics reform movement is gaining momentum. Led by Rep.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 4, 2022
NYSE: AMAM), a position he previously held from 2010 through 2015. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.
Cannabis Law Report
JULY 6, 2021
He was also listed in “Best Doctors in America” in 2007, 2009, and 2010. Johnson, DSc, MD, MPhil, FRCPsych said, “I am pleased to join the Ehave Medical Advisory Board and look forward to working towards bringing psychedelic-assisted therapies to patients experiencing substance use issues. Johnson received the R.
Greencamp
AUGUST 16, 2018
The available body of evidence suggests that besides the lessening of symptoms, cannabis is also capable of slowing down the overall rate of progression of this horrible condition. Modern science hasn’t found a cure for this condition so far, and the most frequent cause of death is respiratory failure due to muscle decay.
Cannabis Law Report
JULY 28, 2021
We look forward to providing continued updates on our intellectual property, research, clinical, regulatory and manufacturing activities for PD-001; our novel oral formulation of cepharanthine, with the aim of working towards a first-in-human, proof-of-concept clinical trial under an FDA IND approval.” ” Next Steps.
Cannabis Law Report
JULY 25, 2022
Conversation Tackles MAPS Research Methadology & Issues Of Abuse In Therapy. Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. Psychedelics Today Podcast Interviews Rick Doblin.
Expert insights. Personalized for you.
144 
Let's personalize your content